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Decoy Receptor 3 (DcR3), a secreted member of the
Tumor Necrosis Factor (TNF) receptor superfamily,
neutralizes three different TNF ligands: FasL, LIGHT,
and TL1A. Each of these ligands engages unique
signaling receptors which direct distinct and critical
immune responses. We report the crystal structures
of the unliganded DcR3 ectodomain and its complex
with TL1A, as well as complementary mutagenesis
and biochemical studies. These analyses demon-
strate that DcR3 interacts with invariant backbone
and side-chain atoms in the membrane-proximal
half of TL1A which supports recognition of its three
distinct TNF ligands. Additional features serve as
antideterminants that preclude interaction with other
members of the TNF superfamily. This mode of inter-
action is unique among characterized TNF:TNFR
family members and provides a mechanistic basis
for the broadened specificity required to support
the decoy function of DcR3, as well as for the rational
manipulation of specificity and affinity of DcR3 and
its ligands.
INTRODUCTION
The mammalian immune system is a complex network regulated
by costimulatory signals transmitted by a multitude of secreted
and cell surface proteins. The human tumor necrosis factor
(TNF) superfamily includes at least 19 members and represents
a major class of the costimulatory molecules. Most TNF ligands
bind unique signaling receptors, and these specific ligand:re-
ceptor interactions direct important and diverse biological
responses ranging from proliferation to apoptosis (Locksley
et al., 2001; Pfeffer, 2003; Ware, 2003). In general, the TNF
ligands are homotrimeric type-II membrane proteins with ecto-
domains that adopt a b sandwich ‘‘jelly-roll’’ fold. The ectodo-
mains of TNF receptors (TNFR) are elongated type-I membrane
proteins containing tandem repeats of one to six cysteine-rich162 Structure 19, 162–171, February 9, 2011 ª2011 Elsevier Ltd All rdomains (CRDs), which bind the interprotomer grooves formed
between adjacent ligand monomers. This mode of interaction
results in ligand:receptor assemblies with 3:3 stoichiometries
that span two interacting cells. The ligand-mediated clustering
of TNFRs directs the recruitment of signaling adaptor proteins,
such as TNF receptor associated factors (TRAFs) or death
domain adaptor proteins, and initiates diverse downstream
signaling pathways.
Some TNFRs are also produced as soluble forms due to alter-
nate mRNA splicing or selective proteolytic cleavage (Cheng
et al., 1994; Locksley et al., 2001; Van Zee et al., 1992). The met-
alloprotease-mediated cleavage of two TNF-a receptors (TNFR1
and TNFR2) has been reported to attenuate proinflammatory
TNF-a-associated signaling, possibly by reducing the amount
of cell surface receptors and by the sequestration/neutralization
of free ligands (Galon et al., 2000; Van Zee et al., 1992). By
analogy, soluble antagonists that block specific pathways have
found widespread clinical use. For instance, Etanercept, a
soluble fusion protein formed between the ectodomain of TNF
receptor 2 (TNFR2) and the Fc region of human immunoglobulin
(Ig), is a leading treatment for autoimmune disorders like rheu-
matoid arthritis (Moreland et al., 1997).
In contrast to most members of the TNFR superfamily, the
gene for Decoy Receptor 3 (DcR3, also known as TNFRSF6B)
does not encode a cytoplasmic or transmembrane segment, re-
sulting in an obligate secreted protein of 300 amino acids
including the signal peptide (Figure 1A). The human DcR3 gene
maps to a chromosomal region (20q13.3) associated with both
cancer and autoimmune diseases (Bai et al., 2000; Kugathasan
et al., 2008; Muleris et al., 1995). DcR3 orthologs have not
been identified in the murine genome, suggesting an important
difference between the murine and human immune systems
(You et al., 2008). In healthy human subjects, low levels of
DcR3 mRNA are detected in a broad range of tissues (Bai
et al., 2000; Pitti et al., 1998), while the expression of DcR3 is
significantly elevated in patients with a range of cancers and
autoimmune diseases (Funke et al., 2009; Pitti et al., 1998; Wu
et al., 2003). Notably, DcR3 is capable of binding and neutralizing
three TNF ligands: FasL, LIGHT, and TL1A (Migone et al., 2002;
Pitti et al., 1998; Yu et al., 1999). These three ligands belong to
the group of conventional TNF ligands, members of which are
characterized by a compact trimeric assembly resembling anights reserved
Figure 1. DcR3 Is a Secreted TNF Receptor that Neutralizes Three
TNF Ligands and Blocks Multiple Signaling Pathways
(A) DcR3 domain structure. DcR3 is composed of a signal peptide (SP), fol-
lowed by four cysteine-rich domains (CRD) and a heparan-binding domain
(HBD) at the C terminus. The numerals above the schematic refer to the
sequence numbers of the last residue in each domain. The DcR3 protein in
this report includes residues V30–S195.
(B) TNF ligands (trimers of rectangles), TL1A (green), LIGHT (blue), and FasL
(yellow), bind distinct signaling TNF receptors (cubes), DR3 (green), HVEM
(blue), LTbR (cyan), and Fas (yellow), directing the proliferation (+) or apoptosis
() of a variety of cell types. The secreted decoy receptor DcR3 (red) plays
a complicated regulatory function by neutralizing the three TNF ligands and
blocking multiple signal transduction pathways.
Structure
The Structure of TL1A:DcR3 Complexinverted-bell shape (Compaan and Hymowitz, 2006). However,
sequence similarity among FasL, LIGHT and TL1A is modest
(30% identity) and each ligand binds different signaling recep-
tors, which trigger distinct cellular responses (Figure 1B).
Recently, the C-terminal region of DcR3, which resides outside
the TNF ligand binding domain, was reported to bind heparan
sulfate proteoglycans (HSPG) and trigger reverse signaling in
antigen presenting cells (APC) (Chang et al., 2006; You et al.,
2008).
Defining the precisemechanistic contributions of DcR3 to host
immunity is complicated by the diverse functions of its three TNF
ligands (Figure 1B). LIGHT and its signaling receptor, HVEM, are
expressed on the surface of T cells and are essential for the
proliferative signaling triggered by T cell-T cell interactions
(Wang et al., 2001). The DcR3-mediated blockade of LIGHT
was shown to reduce T cell activity in vitro and to ameliorate
graft-versus-host responses in vivo (Zhang et al., 2001). In addi-
tion, the engagement of TL1A, expressed on antigen presenting
cells (Bamias et al., 2006), with its signaling receptor DR3,
expressed on activated T cells, promotes T cell proliferation
(Migone et al., 2002) and appears essential for the development
of several inflammatory diseases including Crohn’s disease and
rheumatoid arthritis (Bull et al., 2008; Meylan et al., 2008; Pappu
et al., 2008). Inhibition of TL1A-associated pathways, including
the administration of DcR3, has been suggested as a promising
approach for the treatment of these autoimmune diseases
(Young and Tovey, 2006).
The third DcR3 ligand, FasL, and its signaling receptor, Fas,
are both highly expressed on the surfaces of activated T cells.
In contrast to the immune-stimulatory consequences of the
LIGHT:HVEM and TL1A:DR3 interactions, FasL:Fas engage-Structure 19, 16ment induces apoptosis of T cells and curbs the activation of
immunological responses (Siegel et al., 2000). Disruption of
the FasL:Fas interaction is a major contributor to autoimmune
lymphoproliferative syndrome (ALPS) in humans (Straus et al.,
1999). By competing with Fas and blocking FasL signaling,
DcR3 might accelerate overactive immune responses and
contribute to the development of autoimmune disorders (Funke
et al., 2009; Hayashi et al., 2007).
It is notable that elevated expression of DcR3 is closely corre-
lated with the progression of a variety of cancers (Bai et al., 2000;
Pitti et al., 1998; Takahama et al., 2002), and tumor-secreted
DcR3 has been proposed to facilitate immune evasion by
blocking the apoptotic signals transmitted from FasL and LIGHT
expressed on lymphocytes (Ashkenazi, 2002). Furthermore,
soluble TL1A induces apoptosis in vascular endothelial cells in
an autocrine manner, and neutralization of TL1A by DcR3 was
reported to promote neovascularization and tumor growth
(Yang et al., 2004) (Figure 1B). These tumor-promoting activities
suggest that DcR3 antagonists might provide new avenues for
cancer therapy (Ashkenazi, 2002).
In order to define and potentially manipulate the functional
contributions of DcR3, it is essential to characterize the determi-
nants responsible for its relaxed specificity and decoy strategies.
In this work, we focus on the interactions of DcR3 with its three
conventional TNF ligands, TL1A, FasL, and LIGHT, and report
the crystal structures of the human DcR3 cysteine-rich domains
and two crystal forms of the human TL1A:DcR3 complex. These
studies reveal overall structural similarity to the conventional
TNF:TNFR assemblies and highlight the unique features respon-
sible for the broadened specificity of DcR3. In particular, the third
CRD (CRD3) of DcR3 forms weak and seemingly nonspecific
contacts with the upper region of TL1A, which is thought to be
a major determinant of specificity in the remainder of the TNF
superfamily. Most notably, CRD2 of DcR3makesmajor contacts
with backbone atoms in the lower region of TL1A and it is the
recognition of these invariant features that supports interactions
with the three distinct ligands. Additional structural features in
CRD2 of DcR3 are responsible for restricting the specificity to
these three ligands. These observations are consistent with
a series of complementary biochemical and mutagenesis
analyses. Our findings provide a basis for understanding and
exploiting the roles of DcR3 in a wide range of physiological,
pathological, and therapeutic settings (Figure 1B).
RESULTS
Overall Structure of the TL1A:DcR3 Complex
We determined the crystal structures of human DcR3 cysteine-
rich domain (CRD) protein and its complex with human TL1A
ectodomain in cubic and trigonal crystal forms (Table 1). The
overall organization of the TL1A:DcR3 complex is similar to
that of the canonical TNF ligand:receptor complex structures
(i.e., LTa:TNFR1, PDB code 1TNR; and TRAIL:DR5, PDB code
1D0G) (see Figure S1 available online) (Banner et al., 1993; Hy-
mowitz et al., 1999; Mongkolsapaya et al., 1999), with each
DcR3 molecule contacting the groove between two TL1A
subunits, resulting in an assembly with overall 3:3 stoichiometry
(Figures 2A and 2B). Despite distinct lattice packing, the
TL1A:DcR3 complexes are highly similar in the two crystal forms2–171, February 9, 2011 ª2011 Elsevier Ltd All rights reserved 163
Table 1. Statistics for Data Collection and Refinement
Data Collection
TL1A:DcR3 Trigonal TL1A:DcR3 Cubic Unliganded DcR3
Space group P321 P4332 H32
Unit-cell lengths (A˚) a = b = 74.89 c = 143.13 a = b = c = 161.08 a = b = 130.02 c = 96.03
Wavelength used (A˚) 0.9792 0.9791 0.9791
Resolution range(A˚) 2.45–50.00 2.95–50.00 2.70–50.00
Unique reflections (N) 17,791 15,595 8677
Redundancya 7.7 (7.6) 20.9 (21.2) 7.3 (5.7)
Completeness (%)a 99.9 (100.0) 99.8 (100.0) 99.6 (99.9)
Rmerge
a,b 0.131 (0.99) 0.092 (0.898) 0.073 (0.793)
<I/sigmaI >a 15.3 (3.2) 36.6 (3.9) 18.9 (1.2)
Refinement
Resolution ranges (A˚) 2.4536.23 2.95–25.00 2.90(2.80/3.10)–20.00d
Rwork
a,c 22.3 (23.5) 23.2 (32.1) 28.5 (33.5)
Rfree
a 26.2 (31.4) 26.1 (37.8) 31.5 (34.2)
Completeness (%) 99.9 (100.0) 98.86 (99.73) 88.17 (18.78)
Average B factors (A˚2) 79.9 84.7 36.3
Rms bonds (A˚) 0.006 0.007 0.008
Rms angles () 0.540 1.126 1.212
a Values in parenthesis correspond to the highest resolution bin.
b Rmerge = ShklSi j Ii (hkl) - IðhklÞj / ShklSi Ii (hkl).
c Rwork =
PjFc  Foj/
P
Fo.
d Data after anisotropy correction. (Ellipsoidal truncation with resolution limits of 2.8 A˚ along the c* directions, 3.1 A˚ along the a* and b* directions.)
Structure
The Structure of TL1A:DcR3 Complex(RMSDs of 0.5 A˚ over 143 TL1A Ca atoms and 1.2 A˚ over 107
DcR3 Ca atoms). The most significant difference is the 10
deviation in the angle between CRD2 and CRD3 in DcR3
(Figure 2E).
In both the cubic and trigonal crystal forms of the complex, the
structure of bound TL1A closely resembles that of the previously
reported unbound TL1A, with a typical jelly-roll domain
composed of two b sheets formed by the A0AHCF and B0BGDE
strands (Figure 2C) (Jin et al., 2007; Zhan et al., 2009). The bound
and unbound structures of the TL1A trimer superpose with an
RMSD of 0.584 A˚ over 402 Ca atoms, indicating that TL1A
does not undergo significant tertiary or quaternary reorganiza-
tion upon binding DcR3 (Figure 2C). DcR3 is an elongated mole-
cule composed of four tandem CRDs, which adopt a slightly
kinked organization with a hinge angle between CRD2 and
CRD3 of approximately 40, 30, and 25 in the trigonal complex,
cubic complex and unliganded DcR3 crystal forms, respectively
(Figures 2D–2F). This hinge movement is tangential to the TL1A
trimer and reflects modest intrinsic flexibility between CRD2
and CRD3 which is independent of ligand binding. Both CRD3
and CRD4 lack a canonical disulfide bond present in conven-
tional cysteine-rich domains (Figure S2), and exhibit dynamic
behavior; electron density for CRD3 and CRD4 in both the cubic
form of the complex and the unliganded DcR3 is poor or unde-
tectable and cannot be fully modeled (Figures 2E and 2F). Given
the modest resolution and quality of the electron density, the
disulfide bond connectivity of DcR3 modeled in the crystal
structures was verified by nonreducing tryptic digestion and
FT-ICR-mass spectrometry (Figure S2).
The TL1A:DcR3 interface in the trigonal-packing complex is
highlighted in Figure 3 by rotating one DcR3molecule 180 about164 Structure 19, 162–171, February 9, 2011 ª2011 Elsevier Ltd All ra vertical axis. The DcR3-binding residues on TL1A, defined as
those burying greater than 20% of their solvent accessible
surface area in the interface, can be grouped into three separate
regions: the DE loop (the loop connecting D/E b strands,
magenta in Figures 3A and 3C), the AA’/GH loops (orange),
and the CD/EF loops (cyan). This ligand:receptor recognition
pattern is unique compared with previously reported structures
of TNF:TNFR complexes, and provides a mechanistic basis for
the ability of DcR3 to selectively neutralize FasL, LIGHT, and
TL1A, while precluding interactions with other TNF ligands.
Reduced Contacts in the Specificity-Determining
Membrane-Distal Region
Comparison of the LTa:TNFR1 and TRAIL:DR5 structures
suggests that the receptor binding surfaces of the two TNF
ligands, LTa and TRAIL, can be divided into a lower region prox-
imal to the ligand membrane (below the dotted lines in Figure 4
panels, hereafter referred as ‘‘lower’’) and an upper region distal
to themembrane (above the dotted lines in Figure 4 panels, here-
after referred as ‘‘upper’’) (Banner et al., 1993; Hymowitz et al.,
1999; Kim et al., 2003). In the membrane-proximal lower region,
CRD2 of the two receptors adopt highly similar backbone
conformations and interact with the same loop segments (DE
and AA’ loops) in their cognate ligands. It has been suggested
that these conserved interactions play an important role in
defining the overall geometric and architectural features of the
ligand:receptor assemblies (Hymowitz et al., 1999). In contrast,
in the membrane-distal upper region, CRD3 of the TNFR1 and
DR5 receptors adopt different conformations and interact with
distinct less conserved areas at the top of the ligands. These
interactions in the upper region of the ligand are thought toights reserved
Figure 2. Overall Structure of DcR3 and TL1A
(A and B) Side view (A) and top view (B) of the TL1A:DcR3 complex from the
trigonal crystal form. TL1A is a tight homotrimer, with its three subunits colored
in green, blue, and red. DcR3 (orange) binds the grooves formed between
two TL1A subunits. The structure in (B) is rotated 90 around a horizontal
axis relative to (A).
(C) Structural superposition of DcR3-bound (red) and unbound (green) TL1A.
The TL1A b strands and connecting loops are labeled according to convention.
(D) The structure of DcR3 extracted from the trigonal TL1A:DcR3 complex.
DcR3 has four cysteine-rich domains (CRD), colored in orange, green,
magenta, and blue. Each CRD contains two to three disulfide bonds, repre-
sented as sticks.
(E and F) The structure of DcR3 from the trigonal-packing TL1A:DcR3 complex
(orange) superimposed with that from the cubic-packing complex (magenta,
E or the unliganded DcR3, cyan, F).
See also Figure S1.
Structure
The Structure of TL1A:DcR3 Complexcontrol the specificities between different members of the TNF
and TNFR superfamilies (Banner et al., 1993; Bodmer et al.,
2002; Hymowitz et al., 1999).
To compare the TL1A:DcR3 complex with the LTa:TNFR1 and
TRAIL:DR5 structures, the ligand residues contributing to the
binding interfaces in the three complexes are categorized ac-
cording to their buried surface area in Figure 4 (20%–60% in
yellow and 60%–100% in red). In both LTa:TNFR1 and
TRAIL:DR5, the upper and lower binding regions make signifi-
cant contributions to the binding interfaces (Figures 4A and 4B)
(Banner et al., 1993; Hymowitz et al., 1999). In contrast, the
most heavily buried residues in DcR3-binding interface cluster
to the lower half of the TL1A, while the upper part of TL1Amakes
only modest contact with DcR3 (Figures 4C and 4D). In the
trigonal crystal form of TL1A:DcR3 complex, CRD3 of DcR3
interacts with the bottoms of the CD and EF loops located in
the upper region of the groove formed between two TL1A
subunits (cyan in Figure 3). In the cubic crystal form of the
complex, CRD3 is more disordered and tilted away from TL1A
(Figures 2 and 4), precluding most of the contacts observed in
this region in the trigonal form. The different orientations of
CRD3 in the two TL1A:DcR3 crystal forms lead to varied interac-
tions in this upper region, suggesting that these contacts do not
make significant energetic contributions to binding. This idea isStructure 19, 16supported by our previous studies demonstrating that substitu-
tions of multiple residues in the upper region of TL1A do not
affect DcR3 binding (Zhan et al., 2009). In the LTa:TNFR1,
TRAIL:DR5 and TL1A:DcR3 complexes, the membrane-distal
binding upper patches all primarily involve CRD3. However,
structure-based sequence comparison shows that the CRD3 in
DcR3 is significantly shorter than its counterparts in other recep-
tors (Figure 3B), and this difference may contribute to the
reduced contacts at the upper region of TL1A. Together, these
observations indicate that DcR3 does not form critical interac-
tions with the ‘‘specificity-determining’’ membrane-distal region
of TL1A, consistent with the ability of DcR3 to neutralize three
distinct TNF ligands.
Invariant Binding Determinants in the
Membrane-Proximal Region
In the membrane-proximal lower region, both the trigonal and
cubic crystal forms of the TL1A:DcR3 complex exhibit virtually
identical binding interactions, with CRD2 of DcR3 making two
sets of contacts with two adjacent TL1A subunits (magenta
and orange in Figure 3). As illustrated in Figure 3, one major
binding patch (Magenta) is formed between the DE loop of the
leftmost TL1A subunit and the N-terminal segment of CRD2 of
DcR3. In this patch, the hydroxyl group of Y121 in TL1A forms
a hydrogen bond with the backbone of DcR3 and this residue
also makes hydrophobic contacts with N83, L85, and R89. Addi-
tional polar interactions are formed between the backbone
atoms of S120, E123 and P124 in TL1A and Y84 (backbone)
and R89 (side chain) in DcR3. These polar interactions are sur-
rounded by additional hydrophobic contacts involving S120,
P122 in TL1A and F81, Y84 in DcR3.
Y121 in the DE loop of TL1A is nearly invariant in the conven-
tional TNF ligands (Zhan et al., 2009). Mutations of this Tyr
residue in TL1A and other TNF ligands, including TNF-a, LTa,
FasL, LIGHT, and TRAIL, all severely compromise receptor
binding affinities (Goh et al., 1991; Hymowitz et al., 2000; Rooney
et al., 2000; Schneider et al., 1997; Yamagishi et al., 1990; Zhan
et al., 2009). Following this critical Tyr, Pro122 in TL1A is also
conserved in most conventional TNF ligands and provides
additional contacts to DcR3. However, the other residues in
the DE loop sequences are not conserved among the three
ligands of DcR3 (TL1A, FasL, and LIGHT). Interestingly, the
sequence of TRAIL in this region is almost identical to TL1A (Fig-
ure 3A). Thus, it is notable that DcR3 does not bind TRAIL, but
instead recognizes TL1A, LIGHT, and FasL, which possess
more divergent sequences. In TRAIL:DR5, two hydrophobic resi-
dues (L110 and L114) and two hydrophilic residues (H106 and
D109) from DR5 interact with the side chains of the TRAIL DE
loop (S215, Y216, and D218), all of which are conserved in
TL1A (S120, Y121, and E123, correspondingly) (Figures 3A and
5). However, on the receptor’s side, H106, D109, and L114 of
DR5 are substituted with F81, Y84, and R89 in DcR3, respec-
tively (Figures 3B and 5). These changes in chemical-physical
properties allow DcR3 to form polar interactions with the back-
bone of the ligand DE loop, and surround this interface with
more extensive hydrophobic contacts. The recognition of TL1A
DE loop backbone atoms by DcR3 clearly contrasts the recogni-
tion of TRAIL side-chain atoms by DR5. Consistent with this
model, our previously reported mutagenesis work demonstrated2–171, February 9, 2011 ª2011 Elsevier Ltd All rights reserved 165
Figure 3. Interaction Interface between DcR3 and TL1A
(A and B) Structure-based sequence alignment of TNF ligands (A) and receptors (B). The three separate binding patches in the TL1A:DcR3 interface are colored in
magenta, orange and cyan; homologous residues in the other ligands/receptors are colored accordingly. In the ligand alignment (A), the numbering at the top is
according to TL1A sequence. The secondary structure of TL1A is presented at the bottom, with arrows indicating b–sheets and a cylinder representing the sole
a-helical segment. The labels of b-strands are in accordance to those in Figure 2C. In the receptor alignment (B), arrowed lines below the alignment indicate
boundaries of N/C-terminal regions of a cysteine-rich domain.
(C) ‘‘Open book’’ view of the TL1A:DcR3 interface. One DcR3molecule is rotated 180 around a vertical axis to expose the interfaces. The residues are colored as
in the alignments of (A) and (B).
See also Figure S2 and Table S1.
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The Structure of TL1A:DcR3 Complexthat the S120A/E123A double mutant of TL1A did not signifi-
cantly decrease the binding affinity with DcR3, as would be ex-
pected if the TL1A backbone atoms were involved (Zhan et al.,
2009). Thus, in order to function as a generic receptor that
neutralizes multiple ligands, we propose that DcR3 possesses
broadened specificity as the consequence of recognizing only
the invariant side chain (i.e., Y121) and backbone binding deter-
minants in the DE loop. The inability of DcR3 to bind TRAIL may
be the consequence of antideterminants discussed immediately
below.
Antideterminants Limit More Extensive Promiscuity
As illustrated in Figure 3, the other major membrane-proximal
binding interface (Orange) is formed between the AA’ and GH
loops of the rightmost TL1A subunit and CRD2 of DcR3. In the
C-terminal end of the TL1A AA’ loop, the physical-chemical
properties of the residues corresponding to L56 and G57 are
highly conserved only among the DcR3 binding ligands (Fig-
ure 3A) (Zhan et al., 2009), and may serve to narrow the speci-
ficity of DcR3. These two residues bury 70% of their solvent
accessible area in the interface and form hydrophobic interac-
tions with Y90 in DcR3. The residues corresponding to Y90 in
TNFR1 (S72) and DR5 (R115) are both hydrophilic residues
which make polar contacts with the C-terminal end of the AA’
loops of their cognate ligands. Mutations of charged residues
in the C-terminal end of the AA’ loops of TNF-a, LTa, and
CD40L all significantly reduced receptor binding affinities166 Structure 19, 162–171, February 9, 2011 ª2011 Elsevier Ltd All r(Hymowitz et al., 2000), suggesting critical hydrophilic interac-
tions in this region for these receptor-ligand partners. In contrast,
our mutagenesis studies demonstrated that the C-terminal end
of the AA’ loop of TL1A’s is not critical for DcR3 binding (Zhan
et al., 2009). Thus, the unique hydrophobic interactions between
DcR3 and C-terminal end of the AA’ loop of TL1A may represent
yet another specialized mechanistic feature utilized by DcR3 to
recognize and discriminate TNF ligands. Specifically, while the
hydrophobic residues in this region do not make important
contributions to TL1A:DcR3 binding affinity, they instead may
serve as antideterminants to impair the interactions between
DcR3 and TNF ligands possessing hydrophilic AA’ loops.
At the center of the groove formed between two TL1A
subunits, R36 from the N-terminal segment of the AA’ loop and
T172-E174 at the tip of the GH loop are extensively buried in
the binding interface and make polar interactions with the
C-terminal segment of CRD2 of DcR3 (top of the orange patch
in Figure 3). Consistent with this structural observation, our
previous study revealed that the E174A mutation in TL1A
significantly decreased binding to DcR3 (Zhan et al., 2009).
This hydrophilic region is not conserved between TL1A and the
other TNF ligands, suggesting important contacts that are
unique to the TL1A:DcR3 interaction. Given this sequence diver-
gence, it is likely that DcR3 makes diverse interactions with
TL1A, FasL, and LIGHT in this region, which may partially
account for the different DcR3 binding affinities exhibited by
these three TNF ligands (see below).ights reserved
Figure 4. Comparison of Receptor Binding Interfaces in TNF
Ligands
(A–C) (A) LTa:TNFR1 interface (PDB ID: 1TNR); (B) TRAIL:DR5 interface (PDB
IDs: 1D0G,1D4V); (C) trigonal TL1A:DcR3 interface. In each complex interface,
two TNF ligand subunits are displayed by a surface representation and one
TNF receptor by a green ribbon. Ligand residues with 20%–60% of their
solvent accessible surface area buried in the interface are colored in orange,
and those 60%–100% buried are colored red.
(D) TL1A and DcR3 in the cubic TL1A:DcR3 complex are displayed by surface
representation and green ribbon representations as in panels A-C. The blue
ribbon represents the DcR3 molecule from the trigonal TL1A:DcR3 complex
superimposed onto the cubic TL1A:DcR3 complex.
Structure
The Structure of TL1A:DcR3 ComplexSelf-Assembly of DcR3 Molecules
DcR3 cysteine-rich domains pack as parallel dimers in the
ligand-free crystal and parallel trimers in the trigonal complex
crystal (Figure S1). Consistent with the lack of conserved quater-
nary organization in the crystalline state, sedimentation equilib-
rium analyses of DcR3 cysteine-rich domains showed onlyFigure 5. The DE Loop Interfaces in the TRAIL:DR5 and TL1A:DcR3
Complexes
DR5 (green in A) makes all of its polar interactions with the side-chain atoms of
the TRAIL DE loop (blue). In contrast, DcR3 (green in B) only forms polar inter-
actions with the invariant backbone atoms and a highly conserved tyrosine
residue in the TL1A DE loop (magenta). The binding residues are represented
as sticks, and polar interactions are highlighted by purple dashed lines. The
protein backbones are represented by ribbons.
See also Figure S3.
Structure 19, 16very weak self-association, with an estimated equilibrium disso-
ciation constant (Kd) greater than 2.4 mM, suggesting that at
physiological concentrations (pM concentration in tumor patient
serum; Wu et al., 2003) unliganded DcR3 is predominantly
monomeric (Figure S1).
Side Chains of S120 and E123 Residues
in TL1A Are Critical for DR3 Binding
In the interface formed between DE loop of TL1A and CRD2 of
DcR3, the backbone atoms of TL1A residues S120 and E123
form polar interactions with DcR3. The S120A/E123A TL1A
double mutant only modestly reduced DcR3 binding response
by approximately 35% (Figure S3). In contrast, the S120A/
E123A TL1A mutant significantly reduced the DR3 binding
response by almost 90% (Figure S3). Thus, the side-chain atoms
of S120 and E123 in TL1A make important contributions to the
TL1A:DR3 interaction, while the TL1A:DcR3 interaction is more
dependent on recognition of invariant main chain atoms of
TL1A at these positions.
Interaction of DcR3 Cysteine-Rich Domains
with Immobilized TNF Ligands
Surface plasmon resonance (SPR) analysis revealed that wild-
type (WT) human DcR3 CRDs bind immobilized human TL1A
(Zhan et al., 2009), LIGHT (R&D Systems), and FasL (R&D
Systems) ectodomains with Kds of 56.4 ± 3.7, 14.0 ± 2.0, and
271.4 ± 24.4 nM, respectively (Figure 6). The structure of the
TL1A:DcR3 complex shows that side-chain atoms of L85 and
R89 in CRD2 of DcR3 interact with the TL1A DE loop in the
membrane-proximal region of the ligand. To investigate whether
these DcR3 residues are important determinants for all three TNF
ligands, the L85A/R89A double mutant of DcR3 was expressed
and purified, and its affinities for TL1A, LIGHT, and FasL were
determined as for wild-type DcR3. The binding of the L85A/
R89A mutant DcR3 to all three ligands is significantly lower
than that of WT DcR3 and is too weak to yield confident Kd
values; these interactions cannot be saturated at even the high-
est concentration of DcR3 examined (1000 nM), suggesting
affinities in the mM range or weaker. These results suggest that
all three ligands utilize a common mode of DcR3 recognition.
DISCUSSION
The overall organization of the TL1A:DcR3 interaction is similar
to the previously characterized conventional TNF ligand:recep-
tor complexes, LTa:TNFR1 (Banner et al., 1993) and TRAIL:DR5
(Hymowitz et al., 1999; Mongkolsapaya et al., 1999), with an
elongated receptor bound at the groove formed by adjacent
subunits in the compact homotrimeic ligand, resulting in an
assembly with 3:3 ligand:receptor stoichiometry. The extracel-
lular ligand:receptor binding geometry has been suggested to
impose similar constrains on the cytoplasmic scaffolding and
to facilitate the recruitment of trimeric signaling adaptor proteins
like TRAFs or death domain proteins (Chattopadhyay et al.,
2009). The extracellular C-terminal ends of three TNFRs bound
by conventional TNF ligands are separated by 33 A˚ and 52 A˚ in
the LTa:TNFR1 and TRAIL:DR5 complexes, respectively. The
C termini of each DcR3 CRD construct are separated by approx-
imately 65 A˚ in the TL1A:DcR3 complex, with a modestly flexible2–171, February 9, 2011 ª2011 Elsevier Ltd All rights reserved 167
Figure 6. TNF Ligand Binding Affinities of DcR3
(A–C) The affinities of wild-type (WT) DcR3 cysteine-rich domains (solid line
with circles) and the L85A/R89ADcR3 doublemutant (dotted linewith squares)
to immobilized TL1A (A), LIGHT (B), and FasL (C) were measured by surface
plasmon resonance (SPR). Steady-state analysis reveals that TL1A, LIGHT,
and FasL bind WT DcR3 CRDs with Kd values of 56.4 ± 3.7, 14.0 ± 2.0, and
271.4 ± 24.4 nM, respectively. The L85A/R89A DcR3 double mutant exhibited
significantly lower binding responses to each ligand.
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The Structure of TL1A:DcR3 Complexhinge between CRD2 and CRD3 that results in a range of subtly
different conformations (Figure 2). The greater separation and
intrinsic flexibility present in ligand-bound DcR3 may reflect the
fact that DcR3, being a decoy receptor, does not directly trigger168 Structure 19, 162–171, February 9, 2011 ª2011 Elsevier Ltd All rTNF ligand-mediated signal transduction pathways and thus
need not be compatible with the geometric restraints of cyto-
plasmic signaling molecules.
Full-length DcR3 was reported to bind HSPG via a C-terminal
heparan-binding domain. This interaction transmits reverse
signaling to dendritic cells by crosslinking cell-surface proteogly-
cans (Chang et al., 2006; You et al., 2008). However, all studies
have utilized dimeric and bivalent Ig-fusion proteins of DcR3.
To our knowledge, it is not known whether endogenous mono-
meric DcR3 is capable of crosslinking proteoglycans and subse-
quently transmitting reverse signaling in vivo. The present work
shows that the self-association of DcR3 CRDs is very weak,
with an estimated Kd in the mM range, which contrasts the
ligand-independent association of TNFR1 (Naismith et al.,
1995) (see Supplemental Discussion). After binding HSPG
through its C-terminal HBD, DcR3 alone may not be able to
mediate the crosslinking of the HSPGs; however, binding to
the TNF ligands would assemble three DcR3 molecules into a
complex that could potentially support crosslinking. Thus, our
results suggest that in vivo the HSPG crosslinking and reverse
signaling function associated with the C-terminal end of DcR3
may require the simultaneous binding of TNF ligands through
its N-terminal cysteine-rich domains.
Despite sharing similar organizational features with the
conventional TNF:TNFR assemblies, the binding interface
observed in the TL1A:DcR3 complex exhibits important differ-
ences relative to other conventional complexes, and provides
a mechanistic basis for the broadened specificity and decoy
function of DcR3. Our studies demonstrate that DcR3 lacks
the specificity-defining determinants for interaction with the
membrane-distal region of TL1A, and forms critical interactions
with main chain and conserved side-chain atoms in the
membrane-proximal region of its TNF ligands. This unique
strategy allows DcR3 to recognize and neutralize multiple TNF
ligands through recognition of invariant determinants. Further-
more, DcR3 makes hydrophobic contacts with the residues
conserved only in FasL, LIGHT and TL1A, which may serve as
antideterminants to prevent more widespread promiscuity.
The relaxed specificity of DcR3 is the direct consequence of its
mode of ligand recognition. Notably, osteoprotegerin (OPG), the
only other secreted decoy TNF receptor, also displays promis-
cuity by neutralizing both TRAIL and RANKL (Pitti et al., 1998).
Interestingly, the sequence of DcR3 is most similar to that of
OPG (Figure 3B), and both share a short CRD3, suggesting
that reduced contributions by CRD3 might be utilized by both
DcR3 and OPG to broaden their ligand binding specificity. In
contrast, DcR1, a GPI-linked membrane associated decoy
TNFR, specifically binds and neutralizes a single ligand (TRAIL).
Based on sequence considerations, ligand binding residues in
CRD2 of DcR3 are not conserved in DcR1. Additionally, DcR1
does not share the shortened CRD3 present in DcR3, suggesting
that DcR1 behaves more similarly to the conventional signaling
TNFRs and makes important interactions with both the
membrane-proximal and membrane-distal regions of TRAIL.
DcR3 Interaction Patterns among TL1A, LIGHT,
and FasL
SPR analysis demonstrates that wild-type DcR3 binds LIGHT
approximately 4 and 20 times tighter than TL1A and FasL,ights reserved
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The Structure of TL1A:DcR3 Complexrespectively (Figure 6). This variation in binding affinities is ex-
pected to contribute to the in vivo preferences for TNF ligand
binding and neutralization by DcR3; however, these preferences
will also be critically dependent on the expression levels and
expression patterns of the individual ligands.
Dissection of the interface between DcR3 and TL1A suggests
that the most critical binding interface is formed between the DE
loop of TL1A and the N-terminal CRD2 segment of DcR3. The
L85A/R89A double mutant, which effects two key DcR3 residues
in this interface, exhibits significantly lower binding affinity for
TL1A, LIGHT, and FasL than wild-type DcR3 (Figure 6). This
behavior suggests that LIGHT and FasL recognize DcR3 in
a manner similar to that of TL1A, with residues in the DE loop
making crucial contacts with the N-terminal DcR3 CRD2. Differ-
ences in affinities between DcR3 and its three ligands are likely
due, at least in part, to sequence variation in the ligand AA’ and
GH loopswhich contact theC-terminal segment ofCRD2ofDcR3.
Different TL1A-Binding Mechanisms between DcR3
and DR3
The biological complexity associated with DcR3 is further
increased by competition with the cognate signaling receptors
for TL1A, LIGHT, andFasL. The TL1A-binding affinity of full length
DcR3 (1.8 nM) is in the same range as that of DR3 (6.5 nM), the
signaling receptor of TL1A. (Migone et al., 2002). Sequence
comparison of DcR3 with DR3 shows that CRD2 from these
two receptors have the same disulfide connectivity (Figure 3B).
However, the residues in CRD2 of DcR3 that contact the AA’
andDE loops in TL1Aare generally not conserved inDR3, switch-
ing from predominately hydrophobic in DcR3 to predominately
hydrophilic in DR3. These differences suggest that CRD2 of
DR3 might form more polar interactions with TL1A compared
with DcR3. By substituting conserved hydrophilic residues in
TL1A, it might be possible to identify mutations in TL1A that
compromise binding to the DR3 signaling receptor, while
preserving the interactionwith the DcR3 decoy receptor. Consis-
tent with this notion, the S120A/E123A TL1A double mutant ex-
hibitedsignificantly reducedDR3bindingwhilemaintaininga rela-
tively strong DcR3 binding response (Figure S3). Such soluble
‘‘nonsignaling’’ TL1A mutants would be predicted to have only
a modest effect on normal immune regulation by DR3, but would
offer therapeutic efficacy by specifically inhibiting the immune
evasion function of DcR3 associated with various cancers and
autoimmune diseases (Funke et al., 2009; Ashkenazi, 2002).
The reduced contacts between DcR3 and the membrane-
distal part of TL1A is the consequence of a shortened CRD3 rela-
tive to other TNFR family members. The N-terminal CRD3
segment in DR3 features two putative pairs of disulfide bonds
and is 10 residues longer than its counterpart in DcR3. Therefore,
similar to the LTa:TNFR1 and TRAIL:DR5 complexes (Figures 4A
and 4B), DR3 may utilize this region to form a more extensive
interface with the top of the TL1A molecule, distal to the TL1A
membrane. As a result, the DR3-binding footprint on TL1A may
have a more conventional symmetric distribution between the
upper and lower patches compared with the unusual pattern
observed with DcR3 (Figures 4C and 4D).
In conclusion, DcR3 interacts with invariant atoms located in
the membrane-proximal half of TL1A. This mode of interaction
is distinct from previously characterized TNF ligand:receptorStructure 19, 16complexes, and provides a mechanistic basis for the decoy
strategies utilized by DcR3 to recognize and neutralize multiple
TNF family members. These findings also provide insights into
the regulation of cross-reactivities in the TNF superfamily and
offer a structural basis to engineer TNF ligands and receptors
with broadened or tightened specificities for mechanistic and
therapeutic applications.
EXPERIMENTAL PROCEDURES
Cloning, Expression, Mutagenesis, and Purification of DcR3
and TL1A Proteins
DcR3 cDNAwas amplified from a human skin cDNA library (BioChain) by PCR.
The cysteine-rich domains (CRDs, V30-S195) were cloned into the pMT/BiP/
V5-His A vector (Invitrogen) and cotransfected with the pCoBlast (Invitrogen)
plasmid at 20:1 ratio into Drosophila S2 cells. Stable blasticidin-resistant cell
lines were generated according to the manufacturer’s (Invitrogen) manual.
The secreted DcR3 CRD protein was purified to homogeneity by Ni-NTA
column (QIAGEN) followed by size exclusion chromatography (HiLoad Super-
dex 75; Amersham). Detailed expression and purification protocol can be
found in the Supplemental Experimental Procedures.
The cloning, expression and purification of the TL1A protein was previously
described (Zhan et al., 2009). In this study, theC95S/C135S TL1Adoublemutant
was used in the crystallization of the TL1A:DcR3 complex, as thismutant ismore
resistant to aggregation while exhibiting the same structural stability and DcR3
binding affinity as wild-type protein (Zhan et al., 2009). DcR3 and TL1A point
mutations were generated by QuikChange site-directed mutagenesis (Strata-
gene), and the mutant proteins were purified as described for the wild-type.
Crystallization, Structure Determination, and Refinement
Diffraction quality crystals of unliganded DcR3CRDs and TL1A:DcR3 complex
were obtained by sitting drop vapor diffusion at 17C. Trigonal and cubic
crystal forms of the TL1A:DcR3 complex diffracted to resolutions of 2.45
and 2.95 A˚, respectively. The unliganded DcR3 diffraction data exhibits strong
anisotropy with an effective resolution of 2.9 A˚. All structures were determined
bymolecular replacement and refined by standardmethods, resulting inRwork/
Rfree values of 22.3%/26.2%, 23.2%/26.1%, and 28.5%/31.5% for trigonal
TL1A:DcR3 complex, cubic TL1A:DcR3 complex, and unliganded DcR3,
respectively (Table 1).
Surface Plasmon Resonance Binding Assay
SPR binding assays were performed with a BIAcore 3000 optical biosensor
(Biacore) at 25C, using immobilized recombinant FasL (R&D Systemes),
LIGHT (R&D Systemes) and TL1A C95S/C135S proteins. The wild-type and
mutant DcR3 CRDs proteins were injected over the chip at a series of concen-
trations in random order at a flow rate of 20 ml/min. Experimental details are
provided in the supplementary materials. After subtracting the response of
the blank cell (with no protein immobilized), the averaged maximum response
of each experimental cell was plotted against its corresponding concentration.
The steady-state fits were analyzed with Prism 5 (Graphpad Software),
assuming the one site-total model [binding model equation: Y = Bmax*X/
(Kd+X)], where Bmax is the maximum specific binding; Kd is the equilibrium
binding constant.
ACCESSION NUMBERS
Atomic coordinates and structure factors of the trigonal and cubic TL1A:DcR3
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